Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. (HKG: 1349)
Hong Kong
· Delayed Price · Currency is HKD 2.650
-0.030 (-1.12%)
Nov 18, 2024, 4:08 PM HKT
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co.,Ltd. Income Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | 2018 - 2014 |
|---|---|---|---|---|---|---|---|
Period Ending | Sep '24 Sep 30, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 | Dec '19 Dec 31, 2019 | 2018 - 2014 |
| Operating Revenue | 691.62 | 850.73 | 1,031 | 1,140 | 832.47 | 1,029 | Upgrade
|
| Other Revenue | - | - | - | 0.5 | 1.34 | 0.34 | Upgrade
|
| Revenue | 691.62 | 850.73 | 1,031 | 1,140 | 833.8 | 1,029 | Upgrade
|
| Revenue Growth (YoY) | -32.38% | -17.50% | -9.57% | 36.76% | -18.99% | 38.75% | Upgrade
|
| Cost of Revenue | 64.16 | 74.08 | 86.29 | 81.02 | 66.09 | 77.15 | Upgrade
|
| Gross Profit | 627.46 | 776.66 | 944.87 | 1,059 | 767.72 | 952.14 | Upgrade
|
| Selling, General & Admin | 259.88 | 426.45 | 599.5 | 660.26 | 475.71 | 585.5 | Upgrade
|
| Research & Development | 310.97 | 243.76 | 226.85 | 224.39 | 139.27 | 127.82 | Upgrade
|
| Other Operating Expenses | 12.34 | 5.39 | 6.84 | 6.15 | 4.08 | 5.3 | Upgrade
|
| Operating Expenses | 580.75 | 699.5 | 830.78 | 896.57 | 624.97 | 721.14 | Upgrade
|
| Operating Income | 46.71 | 77.15 | 114.09 | 162.72 | 142.74 | 231 | Upgrade
|
| Interest Expense | -0.81 | -3.07 | -1.54 | -1.06 | -5.6 | -6.3 | Upgrade
|
| Interest & Investment Income | 11.78 | 7.97 | 11.29 | 25.89 | 23.36 | 13.14 | Upgrade
|
| Currency Exchange Gain (Loss) | -1.08 | -1.08 | -0.83 | 0.14 | -0.3 | -1.13 | Upgrade
|
| Other Non Operating Income (Expenses) | 1.06 | -0.42 | -0.14 | 6.21 | -6.7 | -0.29 | Upgrade
|
| EBT Excluding Unusual Items | 57.66 | 80.56 | 122.88 | 193.91 | 153.5 | 236.43 | Upgrade
|
| Gain (Loss) on Sale of Investments | -4.35 | -4.35 | -1.28 | - | - | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -0.84 | 0.3 | 1.92 | 1.78 | 4.6 | 0.79 | Upgrade
|
| Asset Writedown | -4.42 | -5.8 | -1.83 | -2.15 | -0.83 | -6.01 | Upgrade
|
| Other Unusual Items | 49.51 | 26.81 | 10.61 | 22.38 | 19.43 | 15.1 | Upgrade
|
| Pretax Income | 97.56 | 97.53 | 132.29 | 215.92 | 176.7 | 246.31 | Upgrade
|
| Income Tax Expense | -7.25 | -10.92 | -4.98 | 3.54 | 12.44 | 25.66 | Upgrade
|
| Earnings From Continuing Operations | 104.81 | 108.45 | 137.27 | 212.38 | 164.26 | 220.65 | Upgrade
|
| Minority Interest in Earnings | 0.39 | 0.18 | 0.72 | 0.92 | 0.4 | 6.7 | Upgrade
|
| Net Income | 105.2 | 108.63 | 138 | 213.3 | 164.66 | 227.36 | Upgrade
|
| Net Income to Common | 105.2 | 108.63 | 138 | 213.3 | 164.66 | 227.36 | Upgrade
|
| Net Income Growth | -44.94% | -21.28% | -35.30% | 29.53% | -27.58% | 102.76% | Upgrade
|
| Shares Outstanding (Basic) | 1,096 | 1,034 | 1,030 | 1,041 | 989 | 923 | Upgrade
|
| Shares Outstanding (Diluted) | 1,096 | 1,034 | 1,031 | 1,045 | 989 | 923 | Upgrade
|
| Shares Change (YoY) | 0.54% | 0.28% | -1.30% | 5.59% | 7.20% | - | Upgrade
|
| EPS (Basic) | 0.10 | 0.11 | 0.13 | 0.20 | 0.17 | 0.25 | Upgrade
|
| EPS (Diluted) | 0.10 | 0.11 | 0.13 | 0.20 | 0.17 | 0.25 | Upgrade
|
| EPS Growth | -44.07% | -19.19% | -35.00% | 20.17% | -32.44% | 102.76% | Upgrade
|
| Free Cash Flow | -20.37 | -27.95 | 77.96 | 148.78 | 70.59 | 228.85 | Upgrade
|
| Free Cash Flow Per Share | -0.02 | -0.03 | 0.08 | 0.14 | 0.07 | 0.25 | Upgrade
|
| Dividend Per Share | 0.090 | 0.070 | 0.070 | 0.070 | 0.050 | 0.070 | Upgrade
|
| Dividend Growth | 28.57% | 0% | 0% | 40.00% | -28.57% | 0% | Upgrade
|
| Gross Margin | 90.72% | 91.29% | 91.63% | 92.89% | 92.07% | 92.50% | Upgrade
|
| Operating Margin | 6.75% | 9.07% | 11.06% | 14.27% | 17.12% | 22.44% | Upgrade
|
| Profit Margin | 15.21% | 12.77% | 13.38% | 18.71% | 19.75% | 22.09% | Upgrade
|
| Free Cash Flow Margin | -2.94% | -3.29% | 7.56% | 13.05% | 8.47% | 22.23% | Upgrade
|
| EBITDA | 72.05 | 122.85 | 186.92 | 216.5 | 191.62 | 282.09 | Upgrade
|
| EBITDA Margin | 10.42% | 14.44% | 18.13% | 18.99% | 22.98% | 27.41% | Upgrade
|
| D&A For EBITDA | 25.34 | 45.69 | 72.83 | 53.78 | 48.88 | 51.09 | Upgrade
|
| EBIT | 46.71 | 77.15 | 114.09 | 162.72 | 142.74 | 231 | Upgrade
|
| EBIT Margin | 6.75% | 9.07% | 11.06% | 14.27% | 17.12% | 22.44% | Upgrade
|
| Effective Tax Rate | - | - | - | 1.64% | 7.04% | 10.42% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.